Body fat is the main predictor of fibrinogen levels in healthy non-obese men

Metabolism: Clinical and Experimental

Volumn 53, Issue 8, 2004, Pages 984-988

  Bo, Mario ^a,b   Raspo, Silvio ^a   Morra, Fabio ^a   Cassader, Maurizio ^a   Isaia, Giancarlo ^a   Poli, Leone ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Department of Cardiology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID STORAGE; MALE; METABOLISM; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3343017379     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2003.12.009     Document Type: Article

References (64)

1. Mendall M.A., Patel B., Ballam L., et al. C-reactive protein and its relation to cardiovascular risk factors A population-based cross-sectional study. BMJ. 312:1996;1061-1065
2. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979
3. Koenig W., Froelich M., Sund M., et al. C-Reactive Protein (CRP) predicts risk of coronary heart dissease (CHD) in healthy middle-aged men Results from the MONICA-Augsburg Cohort Study, 1984/85-1992. Circulation. 96:1997;I99. (suppl 8, abstr)
4. Kuller L.H., Tracy R.P., Shaen J., et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 144:1996;537-547
5. de Maat M.P., Pietersma A., Kofflard M., et al. Association of plasma fibrinogen levels with coronary heart disease, smoking and inflammatory markers. Atherosclerosis. 121:1996;185-191
6. Ridker P.M., Hennekens C.H., Burin J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:2000;836-843
7. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 101:2000;1767-1772
8. Ridker P.M., Hennekens C.H., Roitman-Johnson B., et al. Plasma concentration of soluble intercellular adhesion molecule 1 and the risk of future myocardial infarction in apparently healthy men. Lancet. 351:1998;88-92
9. Meier-Ewert H.K., Ridker P.M., Rifai N., et al. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem. 47:2001;426-430
10. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 45:1999;2136-2141
11. Ridker P.M. High-sensitivity C-reactive protein Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 103:2001;1813-1818
12. Yarnell J.W.G., Baker I.A., Sweetnam P.M., et al. Fibrinogen, viscosity and white blood cell count are major risk factors for ischemic heart disease The Caerphilly and Speedwell Collaborative Heart Disease Studies. Circulation. 83:1991;836-844
13. Kannel W.B., Wolf P.A., Castelli W.P., et al. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 258:1987;1183-1186
14. Meade T.W., Ellows S., Brozovic M., et al. Hemostatic function and ischemic heart disease Principal results of the Nortwick Park Heart Study. Lancet. 2:1986;533-537
15. Whilelmsen L., Svardsudd K., Korsan-Bengsten K., et al. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med. 311:1984;501-505
16. Lee A.J., Smith W.C.S., Lowe G.D.O., et al. Plasma fibrinogen and coronary risk factors. The Scottish Heart Health Study. J Clin Epidemiol. 43:1990;913-919
17. Landin K., Tengborn L., Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 227:1990;273-278
18. Moller L., Kristensen T.S. Plasma fibrinogen and ischemic heart disease risk factors. Arteroscler Thromb. 11:1991;344-350
19. Balleisen L., Schulte H., Assmann G., et al. Coagulation factors and the progress of coronary heart disease. Lancet. 2:1987;461-464
20. Kannel W.B., D'Agostino R.B., Belanger A.J. Fibrinogen, cigarette smoking and risk of cardiovascular disease Insights from the Framingham Study. Am Heart J. 113:1987;1006-1010
21. Folsom A.R., Conlan M.G., Davis C.E., et al. Relations between hemostasis variables and cardiovascular risk factors in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Ann Epidemiol. 2:1992;481-494
22. Folson A.R., Qamhieh H.T., Flack J.M., et al. Plasma fibrinogen: Levels and correlates in young adults. The Coronary Artery Risk. Development in Young Adults (CARDIA) Study. Am J Epidemiol. 138:1993;1023-1036
23. Pajak A., Broda G., Manolio T.A., et al. Constitutional, biochemical and lifestyle correlates of fibrinogen and factor VII activity in Polish urban and rural populations. Int J Epidemiol. 27:1998;953-961
24. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Center for Disease Control and Prevention and the American Heart Association. Circulation. 107:2003;499-511
25. Whitton C.M., Sands D., Hubbard A.R., et al. A collaborative study to establish the 2nd international standard for fibrinogen, plasma. Thromb Haemost. 84:2000;258-262
26. Visser M., Bouter L.M., McQuillan G.M., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 282:1999;1971-1977
27. Hak A.E., Coen D.A., Bots M.L., et al. Associations of C-reactive protein with measures of obesity, insulin-resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol. 19:1999;198-1991
28. Yudkin J.S., Stehouwer D.A., Emeis J.J., et al. C-reactive protein in healthy subjects Associations with obesity, insulin-resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol. 19:1999;972-978
29. Lemieux I., Pascot A., Prud'homme D., et al. Elevated C-reactive protein. Another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 21:2001;961-967
30. Tchernof A., Nolan A., Sites C.K., et al. Weight loss reduces C-reactive protein levels in obese post-menopausal women. Circulation. 105:2002;564-569
31. Abbasi F., Brown B.W. Jr, Lambendola C., et al. Relationship between obesity, insulin resistance and coronary heart disease risk. J Am Coll Cardiol. 40:2002;937-943
32. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 107:2003;363-369
33. Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events. An 8-year follow-up of 14719 initially healthy American women. Circulation. 107:2003;391-397
34. Ford E.S. Body mass index, diabetes and C-reactive protein among U.S. adults. Diabetes Care. 22:1999;1971-1977
35. Pickup J.C., Mattock M.B., Chusney G.D., et al. NIDDM as a disease of the innate immune system Association of acute phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40:1997;1286-1292
36. McLaughlin T., Abbasi F., Lambendola C., et al. Differentation between obesity and insulin-resistance in the association with CRP. Circulation. 106:2002;2908-2912
37. Reaven G. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation. 106:2002;286-288
38. Yudkin J.S., Kumari M., Humphries S.R., et al. Inflammation, obesity, stress, and coronary heart disease Is interleukin-6 the link? Atherosclerosis. 148:2000;209-214
39. Humpries S.E., Green F.R., Thoma A.E., et al. Genetic control of plasma fibrinogen levels An example of gene-environment interaction in the etiology of a multifactorial disorder. Lindsten L., Pettersen U. Etiology of Human Disease at the DNA-Level. 1991;115-128 Raven, New York, NY
40. Le J., Vilceck J. Interleukin-6 A multifactorial cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 61:1989;588-602
41. Heinrich P.C., Castell J.V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 265:1990;621-636
42. Shea S., Isasi C.R., Couch S., et al. Relations of plasma fibrinogen level in children to measures of obesity, the (G-455→A) mutation in the beta-fibrinogen promoter gene, and family history of ischemic heart disease The Columbia University Biomarkers Study. Am J Epidemiol. 150:1999;737-746
43. Stewart A.D., Hannan W.J. Prediction of fat and fat-free mass in male athletes using dual x-ray absorptiometry as the reference method. J Sports Sci. 18:2000;263-274
44. Marcus M.A., Wang J., Thornton J.C., et al. Anthropometrics do not influence dual x-ray absorptiometry (DXA) measurement of fat in normal to obese adults A comparison with in-vivo neutron activation analysis (IVNA). Obese Res. 5:1997;122-130
45. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502
46. Roberts W.L., Sedrick R., Moulton L., et al. Evaluation of four automated high-sensitivity C-reactive protein methods Implications for clinical and epidemiological applications. Clin Chem. 46:2000;461-468
47. Roberts W.L., Moulton L., Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications. Part 2. Clin Chem. 47:2001;418-425
48. Ledue T.B., Weiner D.L., Sipe J.D., et al. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem. 35:1998;745-753
49. Bastard J.P., Jardel C., Bruckert E., et al. Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 85:2000;3338-3342
50. Mohamed-Ali V., Goodrick S., Rawesh A., et al. Subcutaneuous adipose tissue releases interleukin-6 but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 82:1997;4196-4200
51. Bastard J.P., Grimaldi A., Jardel C., et al. A simple index of insulin resistance. Diabetes Metab. 23:1997;87-88
52. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 21:2003;1011-1053
53. Mendall M.A., Patel P., Asante M., et al. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart. 78:1997;273-277
54. Bastard J.P., Jardel C., Delattre J., et al. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 99:1999;2221-2222
55. Stone M.C., Thorp J.M. Plasma fibrinogen - A major coronary risk factor. J R Coll Gen Pract. 35:1985;565-569
56. Baker I.A., Eastham R., Elwood P.C., et al. Haemostatic factors associated with ischemic heart disease in men aged 45 to 64 years. The Speedwell Study. Br Heart J. 47:1982;490-494
57. Rosengren A., Wilhelmsen L.W., Tsipogianni A., et al. Social influences and cardiovascular risk factors as determinants of plasma fibrinogen concentration in a general population sample of middle-aged men. Br Med J. 300:1990;634-638
58. Kannel W.B., D'Agostino R.B., Belanger A.J. Fibrinogen, cigarette smoking, and risk of cardiovascular disease; insights from the Framingham Study. Am Heart J. 113:1987;1006-1010
59. Niort G., Bulgarelli M., Cassader M., et al. Effect of short term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis. 71:1988;113-119
60. Bo M., Bonino F., Neirotti M., et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology. 42:1991;106-113
61. Rosenson R.S., Tangney C.C., Schaefer E.J. Comparative study of HMG-CoA reductase inhibitors on fibrinogen. Atherosclerosis. 155:2001;463-466
62. Trip M.D., van Wissen S., Smilde T.J., et al. Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogn levels and on carotid intima media thickness in patients with familial hypercholesterolemia. Am J Cardiol. 91:2003;604-606
63. Bo M., Nicolello M.T., Fiandra U., et al. Treatment of heterozygous familial hypercholesterolemia Atorvastatin vs simvastatin. Nutr Metab Cardiovasc Dis. 11:2001;17-24
64. Manson J.E., Hu F.B., Rich-Edwards J.W., et al. A prospective study of walking as compared with vigorous exercise in the prevention of coronary heart disease in women. N Engl J Med. 341:1999;650-658